| |
Wednesday, May 14, 2025 | 11am ET / 8am PT Biotech success isn’t just about great science—it’s about building a compelling commercial narrative from day one. Join us to explore how early commercialization planning, powered by real-world insights, can maximize an asset’s potential. Our discussion will uncover strategies to integrate commercial thinking into R&D. Register now.
|
|
Today’s Big NewsApr 23, 2025 |
| By Zoey Becker CEOs from European drugmakers Sanofi and Novartis have inked a letter in The Financial Times urging the European Union to set drug prices relative to those in the U.S., among other measures. The chief executives argued that the move is necessary to prevent the continued pivot of European drugmakers toward more lucrative biopharma markets like China and the U.S. |
|
|
|
By Darren Incorvaia Roche’s Genentech has inked a deal with Repertoire Immune Medicines aimed at discovering and developing T cell-targeted medicines in the autoimmune disease space. |
By Angus Liu Schizophrenia drug Cobenfy, a key component in Bristol Myers Squibb’s plan to navigate a transition period of major loss of exclusivity, has hit a phase 3 setback. |
By Conor Hale As part of its quarterly earnings report, Intuitive said it expects tariffs to increase its cost of sales by about 1.7% of its annual revenue before the end of this year. |
|
Tuesday, May 6, 2025 | 9am ET / 6am PT This webinar will explore how to use AI-driven tools for timely data-driven decisions that are critical to securing approvals, expediting market entry and sustaining competitive strength. Register now.
|
|
By Andrea Park Gilead Sciences and Sophia Forum, a London-based charity, have launched a campaign to improve HIV care and outreach for women in the U.K.—a group that, according to the partners, has long been overlooked in the nation’s response to the epidemic. |
By Gabrielle Masson Vanda Pharmaceuticals is suing the FDA again, this time alleging the agency is unlawfully delaying a hearing to discuss the rejection of the biotech's stomach disorder drug last September. |
By Kevin Dunleavy Akeso and Summit Therapeutics’ PD-1/VEGF bispecific antibody ivonescimab has posted another phase 3 trial win in lung cancer, this time as part of a chemotherapy combination. |
By Conor Hale Ypsomed plans to trade its insulin pump arm to a new Swiss medtech, TecMed, in a deal worth up to 420 million francs or about $513 million. |
By Darren Incorvaia The Department of Health and Human Services is cutting off funding to the long-running Women’s Health Initiative in September, a move that leaves the fate of one of the world's largest women’s health studies hanging in the balance. |
By Nick Paul Taylor Paul Reider has followed Coherus BioSciences’ last biosimilar product out the door. As the biotech completes its pivot from biosimilars to novel immuno-oncology programs, Reider has resigned as chief commercial officer to pursue other opportunities. |
By Darren Incorvaia Bayer is boosting its precision oncology efforts with a molecular database from health tech firm ConcertAI. |
Fierce podcastsDon’t miss an episode |
| | This week on “The Top Line,” we unpack the latest tariffs from the Trump administration and their potential impact on the life sciences industry. |
|
|---|
|
|
|
Wednesday, May 28, 2025 | 11am ET / 8am PT Join us to learn more about Integrated Drug Discovery (IDD), and explore the complexity of integrating multidisciplinary functions, including chemistry, biology, pharmacology, project and data management, advanced technologies, and regulatory compliance. Learn how to navigate the drug discovery journey and overcome common challenges. Register now.
|
|
| eBookTypical vaccine development timelines have averaged 10 years, but the time from the SARS-CoV-2 genetic sequence’s release to the submission of the first vaccine clinical trial data for regulatory review was a mere 314 days. In IQVIA Laboratories’ Vaccine eBook we focus on how contract research organizations (CROs) can best leverage strategic partnerships with sponsors to prepare for the next pandemic. Sponsored by: IQVIA |
| WhitepaperIs your clinical trial data truly reliable? Learn how a combined approach using Imaging Core Labs and Endpoint Adjudication Committees (EAC) can minimize risk, control costs, and strengthen your study from the ground up. Don’t leave success to chance—arm yourself with the insights to stay ahead. Sponsored by: WCG |
| ResearchWe interviewed 15 biopharma leaders on the critical success factors for building a Best Practice customer-facing organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
